Bingfang Yan

Bingfang Yan

Associate Dean

Associate Dean for Research and Graduate Affairs

Medical Sciences Building


Pharmacy College of Pharmacy - 0514

Professional Summary

The research program in this laboratory has concentrated on: drug metabolism with a focus on carboxyl­esterases, nuclear receptors with a focus on the preg­nane X receptor (PXR), circadian regulation with a focus on differentially expressed in chon­dro­cytes 1 (DEC1), and drug delivery with nanotechnology.  The research theme, featured by pharmacogenomic approaches, targets interactions among genes, drugs, herbs, nutrients, cytokines and their interplay.  This laboratory has published extensively in drug metabolism, hepatotoxicity, oncological signaling and drug delivery.  This laboratory is one of the first to clone and characterize the gene encoding PXR, and the gene encoding DEC1. PXR is a master regulator for drug-metabolizing enzymes and transporters, whereas DEC1 is a circadian regulator with oncogenic involvement.  Several milestone findings from this laboratory have gained global attentions and were reported by public and professional media outlets such as USA Today and Doctors’ Guide.

Research Support

Grant: #R01EB018748 Investigators:Yan, Bingfang 06-01-2018 -06-30-2020 National Institute of Biomedical Imaging and Bioengineering Biodegradable hollow CUS nanoparticles for photothermal cancer therapy Role:PI $316,403.00 Active

Grant: #0006003/062818 Investigators:Yan, Bingfang 06-01-2018 -08-31-2019 National Institute of General Medical Sciences Signaling of the Pregnane X Receptor Role:PI $345,155.00 Active Level:Federal

Grant: #R21AI153031 Investigators:Yan, Bingfang 09-04-2020 -08-31-2022 National Institute of Allergy and Infectious Diseases Metabolic basis for lipid abnormality with anti-HIV tenofovir prodrugs Role:PI $200,937.00 Awarded Level:Federal

Grant: #5R21AI153031-02 NCE Investigators:Yan, Bingfang 09-04-2020 -08-31-2022 National Institute of Allergy and Infectious Diseases Metabolic basis for lipid abnormality with anti-HIV tenofovir prodrugs Role:PI 0.00 Awarded Level:Federal

Grant: #R21HD109411 Investigators:Yan, Bingfang 08-15-2022 -07-31-2024 National Institute of Child Health and Human Development Circular RNA regulators of common drug-eliminating genes Role:PI 202500.00 Awarded Level:Federal

Grant: #R01AA030486 Investigators:; Blackard, Jason; Brown, Jennifer; Robertson, Jaime; Welge, Jeffrey; Yan, Bingfang 09-10-2022 -07-31-2027 National Institute on Alcohol Abuse and Alcoholism Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination Role:PI 721672.00 Awarded Level:Federal

Grant: #R01AI172959 Investigators:; Welge, Jeffrey; Yan, Bingfang 03-08-2023 -02-29-2028 National Institute of Allergy and Infectious Diseases Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir Role:PI 423312.00 Awarded Level:Federal

Grant: #R21HD112071 Investigators:Yan, Bingfang 08-08-2023 -07-31-2025 National Institute of Child Health and Human Development Functional connection between the growth factor independence-1b and post-neonatal regulation of biotransformation genes Role:PI 445500.00 Awarded Level:Federal


Peer Reviewed Publications

Marczak MM, Yan B (2017. ) Circadian rhythmicity: A functional connection between differentiated embryo-chondrocyte-expressed gene 1 and small heterodimer partner. .Arch Biochem Biophys, , 631 ,11-18

Hu J, Wang Y, Mao Z, Ning R, Liu W, Xiong J, Yan B, Yang J (2017. ) Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling pathway .Biochem Pharmacol, , 136: ,109-121

Shen Y, Yan B (2017. ) Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil .J Hepatol, , 66: ,660-661

Ning R, Zhan Y, He S, Hu J, Zhu Z, Hu G, Yan B, Yang J, Liu W (2017. ) Interleukin-6 induces DEC1, promotes DEC1 interaction with RXRαand suppresses the expression of PXR, CAR and their target genes. .Front Pharmacol., , 8: ,866

Wu L, Hafiz MZ, Guan Y, He S, Xiong J, Liu W, Yan B, Li X, Yang J (2017. ) 17β-Estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes. Eur J Pharmacol. , , 819: ,98-107

Li Y, Cupo M, Guo L, Scott J, Chen YT, Yan B, Lu W (2017. ) Enhanced reactive oxygen species through direct copper sulfide nanoparticle-doxorubicin complexation. .Nanotechnology. , , 28: ,505101.

Vachirayonsti T, Yan B (2016. ) MicroRNA-30c-1 suppresses the pregnane X receptor by targeting the 3’-untranslated region and alters the expression of its target gene cytochrome P450 3A4. BBA-Gene Regulatory Mechanisms. , , 1859: ,1238–1244.

Chen YZ, Trzoss L, Yang D, Yan B (2015. ) Ontogenic expression of carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: Postnatal surge and organ-dependent regulation. .Toxicology. , , 330: ,55-61

Chen Y, Valanejad L, Song X, Valanejad L, Verma R, You S, Yan B, Shiffka S, Hargreaves L, Nadolny C, Deng R (2015. ) ) Estrogen and estrogen receptor-α mediated transrepression of bile salt export pump .Mol Endocrinol. , , 29: ,613-626

Vachirayonsti T, Yang D, Yan B (2015. ) Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4 and up-regulating liver-enriched inhibitory protein. .Toxicol Sci. , , 144:382-392. ,382-392.

Xu J, Donepudi AC, More VR, Kulkarni SR, Li L, Guo L, Yan B, Chatterjee T, Weintraub N, Slitt AL (2015. ) Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice .Obesity. , , 23: ,335-344

Song X, Vasilenko A, Chen Y, Valanejad L, Verma R, Yan B, Deng R (2014. ) Transrepression of BSEP by 17beta-estradiol in Intrahepatic Cholestasis of Pregnancy through ERalpha/FXR interaction. .Hepatology., , 60: ,1993-2007

Guo L, Yan DD, Yang D, Li Y, Wang X, Zalewski O, Yan B, Lu W (2014. ) Combinatorial photothermal and immunocancer therapy using chitosan-coated hollow copper sulfide nanoparticles. .ACS Nano., , 8: ,5670-5681

Guo L, Panderi I, Yan DD, Szulak K, Li Y, Chen YT, Ma H, Niesen D, Seeram NP, Ahmed A, Yan B, Pantazato D, Lu W A comparative study of hollow CuS nanoparticles and hollow gold nanospheres on degradability and toxicity. .ACS Nano. , , 7: ,8780-8793.

Song X, Chen Y, Valanejad L, Kaimal R, Stoner M, Yan B, Deng R Mechanistic Insights into Isoform-dependent and Species-specific Regulation of Bile Salt Export Pump by Farnesoid X Receptor. .J Lipid Res. , , 54: ,3030-3044.

Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anticancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug. .Brit J Pharmacol. , , 168: ,1989-1999.

Xiao D, Shi D, Yang D, Barthel B, Koch TH, Yan B Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound clinical implications in the activation of anticancer prodrugs. .Biochem Pharmacol. , , 85: ,439–447

Chen Y, Song X, Vasilenko A, Valanejad L, More V, Qiu X, Chen W, Lai Y, Slitt A, Stoner M, Yan B, Deng R Bile salt export pump is dysregulated with altered farnesoid x receptor isoform expression in patients with hepatocellular carcinoma tissues. .Hepatology. , , 57: ,1530-1541.

Mao Z, Luan X, Cao G, Liu W, Xiong J, Hu G, Chen R, Ning R, Shang W, Yang J, Yan B DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes. .Biochem Pharmacol. , , 84: ,701-711

Contact Information

Research - Yan's Lab
231 Albert Sabin Way
Cincinnati  Ohio, 45229